Status:
COMPLETED
Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens
Lead Sponsor:
Allergopharma GmbH & Co. KG
Conditions:
Pollen Allergy
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
The aim of this clinical trial is to show safety and efficacy of the allergoid preparation of birch pollen allergens in the treatment of birch allergic patients in a representative number of patients.
Detailed Description
Type I allergy is an immune-disorder which stems from the formation of IgE antibodies against proteins and glycoproteins from plants, insects, animals and fungi, most of which for healthy subjects are...
Eligibility Criteria
Inclusion
- Rhinitis
- Rhinoconjunctivitis
- Positive skin prick test to birch pollen
- Positive radioallergosorbent test (RAST) to birch pollen
- Positive provocation test result to birch pollen
Exclusion
- Serious chronic diseases
- Other perennial allergies
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
253 Patients enrolled
Trial Details
Trial ID
NCT00263627
Start Date
June 1 2005
End Date
March 1 2010
Last Update
July 3 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Allergopharma Joachim Ganzer KG
Reinbek, Germany, 21465